Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
ClinicalTrials.gov study NCT06585501. IPD Sharing: NO. Countries: 1. Publications: 0.
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
ClinicalTrials.gov study NCT06599216. IPD Sharing: UNDECIDED. Countries: 1. Publications: 19.
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
ClinicalTrials.gov study NCT04281641. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
ClinicalTrials.gov study NCT03481998. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
ClinicalTrials.gov study NCT02131506. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety Study of MGAH22 in HER2-positive Carcinomas
ClinicalTrials.gov study NCT01148849. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
ClinicalTrials.gov study NCT01996267. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
ClinicalTrials.gov study NCT00887536. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
ClinicalTrials.gov study NCT05275777. IPD Sharing: NO. Countries: 1. Publications: 10.
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
ClinicalTrials.gov study NCT05152147. IPD Sharing: NO. Countries: 33. Publications: 2.
Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
ClinicalTrials.gov study NCT02307227. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
ClinicalTrials.gov study NCT04510285. IPD Sharing: YES. Countries: 1. Publications: 0.
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
ClinicalTrials.gov study NCT04152057. IPD Sharing: NO. Countries: 1. Publications: 1.
99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer
ClinicalTrials.gov study NCT04267900. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
ClinicalTrials.gov study NCT04448886. IPD Sharing: YES. Countries: 1. Publications: 0.
DESTINY Breast Respond HER2-low Europe
ClinicalTrials.gov study NCT05945732. IPD Sharing: NO. Countries: 10. Publications: 1.
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
ClinicalTrials.gov study NCT02514681. IPD Sharing: NO. Countries: 1. Publications: 5.
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast
ClinicalTrials.gov study NCT01805908. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
ClinicalTrials.gov study NCT04296370. IPD Sharing: NO. Countries: 1. Publications: 1.
Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
ClinicalTrials.gov study NCT00724360. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.